of esophageal squamous cancer, emphasizing the harmful effects of excessive drinking. This risk is people who lack acetaldehyde and dehydrogenase in the body. In April, the study was published in Journal of Theoracic Oncology.
AP-T: Proton pump inhibitors can treat eosinophilic esophagealitis.
Time of Update: 2020-09-19
bone pain, acid, heartache and other discomfort, children are mainly manifested in food rejection and malnutrition. Perverted reactions caused by food allergies may be involved in the pathogenesis of eosinophilic esophitis, so 71 percent
Nature Medicine: Genome sequencing predicts the risk of esophageal cancer in advance, especially in patients with precancer lesions.
Time of Update: 2020-09-19
have now developed a statistical model that uses genomic data to accurately predict whether barrett's risk of cancer is high or low.
Studies have shown that drinking overheated tea increases the risk of esophageal cancer.
Time of Update: 2020-09-16
, drinking more than 700 milliliters of hot tea (more than 60 degrees Celsius) has a 90 percent increased risk of esophageal cancer, according to research.
The first-line treatment of esophageal cancer Keytruda combination therapy significantly improved the total survival of patients.
Time of Update: 2020-09-15
it has been approved in the United States and China as a single drug therapy, second-line treatment of tumor expression PD-L1 (CPS-10) of relapsed localized advanced or metastatic esophageal squamous cell carcinoma patients.
After surgery for esophageal cancer and gastroesophageal connecting cancer, Odivo (Navuliyu
Time of Update: 2020-09-12
, and the progress-free survival (PFS) assessed by the Independent BlindNess Central Review Committee (BICR). Key secondary endpoints include CPS1 patients treated with Navuliyu mono-anti-combination chemotherapy, as well as OS from all random patients
Line therapy for gastric/esophageal cancer BMS immuno combination therapy reached the clinical end of phase 3.
Time of Update: 2020-09-11
addition, the CheckMate-649 study evaluated the effectiveness of Odivo's combined epipentherapy chemotherapy for patients with stomach cancer, gastroesophageal connecting cancer, or esophageal adenocarcinoma.
First-line treatment of stomach cancer and esophageal cancer! Odivo (Navuliyu monoanti
Time of Update: 2020-09-11
addition, the CheckMate-649 study evaluated the effectiveness of Odivo's combined epipentherapy chemotherapy for patients with stomach cancer, gastroesophageal connecting cancer, or esophageal adenocarcinoma.
O medicine and chemotherapy and then "group" stomach cancer esophageal cancer patients will usher in a new treatment!
Time of Update: 2020-09-09
Recently, "O-drug" Navuliyu monoanti (commodity name: Odivo) combined chemotherapy in the first-line treatment of tumor expression PD-L1 and comprehensive score (CPS) of 5 metastatic stomach cancer, gastroesophageal connection (GEJ) cancer or esophageal adenocarcinoma Phase III clinical trials.
Scientists say that drinking hot tea is prone to esophageal cancer.
Time of Update: 2020-09-07
Original title: Scientists say drinking hot tea is more likely to cause esophageal cancer An international team of researchers has found that drinking hot tea increases the risk of esophageal cancer, according to scientific news site Eurekalert!
The phase III study of Odivo Assisted Therapy III after esophageal cancer and gastroesophageal connecting cancer reached the main endpoint.
Time of Update: 2020-09-05
Guide: Odevo is the first and only treatment to be shown to be effective in patients with esophageal cancer and gastroesophageal connecting cancer who have underwent new assisted chemotherapy and surgical removal. . Esophageal cancer
Line therapy for gastric/esophageal cancer BMS immuno combination therapy reached the clinical end of phase 3.
Time of Update: 2020-09-05
addition, the CheckMate-649 study evaluated the effectiveness of Odivo's combined epipentherapy chemotherapy for patients with stomach, gastroesophageal connecting or esophageal adenocarcinoma.
Esophageal cancer immunotherapy is making great progress! Mercedon Keytruda (Nerida) and chemotherapy first-line therapy Phase III clinical success!
Time of Update: 2020-09-05
on an interim analysis conducted by the Independent Data Monitoring Board, the Keytruda plus chemotherapy group OS and PFS showed statistical and clinical improvements in the intentional therapy (ITT) group compared to the placebo-and-chemotherapy group.
Esophageal cancer immunotherapy is making great progress! Mercedon Keytruda (Nerida) and chemotherapy first-line therapy Phase III clinical success!
Time of Update: 2020-09-05
on an interim analysis conducted by the Independent Data Monitoring Board, the Keytruda plus chemotherapy group OS and PFS showed statistically and clinically significant improvements in the intentional therapy (ITT) group compared to the placebo
After surgery for esophageal cancer and gastroesophageal connecting cancer, Odivo (Navuliyu
Time of Update: 2020-09-04
results show that Odevo combined chemotherapy will hopefully change the first-line treatment pattern of stomach cancer, gastroesophageal joint cancer or esophageal adenocarcinoma, and become a new standard of treatment for such patients.
survival and non-progressant survival of patients with advanced esophageal cancer.
Time of Update: 2020-09-04
Merck announced that its key Phase 3 KEYNOTE-590 trial for the first-line treatment of patients with localized advanced or metastatic esophageal cancer with anti-PD-1 monoantigen KEYTRUDA chemotherapy (shunplatin plus 5-fluorouracil) reached
